See the full summit details here.
The 7th IPF Summit, a premier event in the field of pulmonary fibrosis research, is set to take place from September 19 to 21, 2023, in the vibrant city of Boston. With a dynamic lineup of features, speakers, and sessions, this summit promises to be a hub of knowledge exchange and networking for professionals dedicated to advancing disease-modifying pulmonary fibrosis drugs.
Bringing together over 80 biopharma companies and 15 event partners, the summit serves as a unique platform for sharing insights and innovation. Kicking off the conference is the Pre-Conference Seminar Day, encompassing three tracks focused on Emerging Biology, Translational Science, and Clinical Developments to cater to different stages of the drug development pipeline.
A highlight of the event for 2023 is the Ambassador Evening, dedicated to celebrating research and development for IPF therapeutics. This networking-focused evening, aptly timed during Pulmonary Fibrosis Awareness Month, offers attendees the opportunity to engage with the IPF community and strengthen connections while hearing from key leaders in the IPF community in a relaxed atmosphere.
The conference agenda itself boasts an impressive roster of over 43 expert speakers, each contributing exclusive data and insights to the field. Distinguished speakers include Fernando Martinez from Weill Cornell Medicine, Toby Maher from USC, Gisli Jenkins from Imperial College London, and Caroline Owen from AstraZeneca, among others. With sessions spanning topics including clinical trial optimization, novel therapies, precision medicine and more, attendees will gain comprehensive insights into the latest advancements in IPF research.
Year on year, attendees emphasize the value of the IPF Summit in fostering collaboration and driving progress. Industry professionals praise the event as an essential platform for networking, learning about emerging research, and understanding the latest developments in biomarker discovery and clinical science.
Speaking of the summit, Rohit Batta, CMO at Vicore Pharma said: ““I’ve thoroughly enjoyed attending the IPF Summit – a conference for innovators – it’s a premier event for therapeutic advancements in a fatal lung disease”.
The 7th IPF Summit offers a unique opportunity for researchers, clinicians, and industry experts to come together, learn from each other, and collectively advance the understanding and treatment of pulmonary fibrosis. As the summit continues to evolve, it remains a pivotal force in propelling IPF research forward, ultimately improving the lives of patients affected by this debilitating condition.
Don’t miss your chance to join the community in Boston this September. See the full agenda, speaker line-up and registration options on the event website here.